目的 观察消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期非小细胞肺癌（NSCLC）的临床疗效。方法 选择鄂东医疗集团黄石市中心医院2013年2月-2015年1月治疗的ⅢB和Ⅳ期NSCLC患者106例，随机分为吉西他滨和卡铂化疗对照组与消癌平注射液联合吉西他滨和卡铂化疗观察组，每组53例。比较两组近远期临床疗效以及不良反应。结果 治疗4个周期后，观察组的治疗有效率和控制率分别为39.6%和77.4%；对照组的有效率和控制率分别为35.8%和75.5%，两组比较差异无统计学意义。观察组白细胞下降、血红蛋白下降和血小板下降率分别为41.5%、37.7%和45.3%，显著低于对照组的64.2%、62.3%和69.8%（P<0.05）。观察组肾功能损伤、肝功能损伤、恶心、呕吐、头晕、头痛、腹泻和便秘发生率与对照组比较无显著差异。观察组中位生存时间8.4月，肿瘤进展时间5.3个月，1年生存率26.4%；对照组中位生存时间7.7月，肿瘤进展时间4.2个月，1年生存率为11.3%，两组比较差异有统计学意义（P<0.05）。结论 消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期NSCLC，可以降低化疗药的血液学毒性，提高远期临床疗效。

Objective To observe the clinical effect of Xiaoaiping Injection combined with gemcitabine and carboplatin in the treatment of IIIB and IV non-small cell lung cancer (NSCLC).Methods Totally 106 NSCLC patients from Huangshi Central Hospital of Edong Medical Group were sellected in this study. The patients were divided into gemcitabine and carboplatin control group (n=53) and Xiaoaiping Injection combined with gemcitabine and carboplatin observation group (n=53). The clinical efficacy and adverse reactions were compared between two groups.Results After four cycles of treatment, the effective rate and control rate in observation group were 39.6% and 77.4%, and those in control group were 35.8% and 75.5%. There was no significant difference between the two groups. The decline rates of white blood cells, hemoglobin, and platelet in observation group were 41.5%, 37.7%, and 45.3%, which were significantly lower than those of 64.2%, 62.3%, and 69.8% in control group (P<0.05). There was no significant difference of renal function injury, liver function damage, nausea, vomiting, dizziness, headache, diarrhea, and constipation between two groups. In observation group, the median survival time was 8.4 months, time to tumor progression was 5.3 months, and 1 year survival rate was 26.4%. In control group, the median survival time was 7.7 months, time to tumor progression was 4.2 months, and 1 year survival rate was 11.3%. There was significant difference between two groups (P<0.05).Conclusion Xiaoaiping Injection combined with gemcitabine and carboplatin can reduce the hematologic toxicity of chemotherapy drug in the treatment of IIIB and IV NSCLC, and improve long-term clinical outcomes.combined with gemcitabine and carboplatin can reduce the hematologic toxicity of chemotherapy drug in the treatment of IIIB and IV NSCLC, and improve long-term clinical outcomes.